Integral Health Asset Management’s AstraZeneca AZN Stock Holding History

Integral Health Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$49.3M	Buy	250,000 +75,000	+43%	+$14.5M	2.36%	14
2025 Q4	$32.2M	Buy	175,000 +25,000	+17%	+$4.38M	1.6%	16
2025 Q3	$23M	Buy	150,000 +50,000	+50%	+$7.57M	1.56%	17
2025 Q2	$14M	Buy	+100,000	New	+$14M	1.28%	28
2025 Q1	–	Sell	-112,500	Closed	-$14.7M	–	84
2024 Q4	$14.7M	Buy	+112,500	New	+$15.8M	1.26%	28
2023 Q1	–	Sell	-70,000	Closed	-$9.49M	–	72
2022 Q4	$9.49M	Buy	+70,000	New	+$8.78M	1.99%	21
2022 Q3	–	Sell	-117,415	Closed	-$15.5M	–	68
2022 Q2	$15.5M	Buy	117,415 +67,415	+135%	+$8.85M	3.19%	7
2022 Q1	$6.63M	Hold	50,000	–	–	1.73%	20
2021 Q4	$5.83M	Buy	+50,000	New	+$5.88M	1.61%	26
2020 Q3	–	Sell	-62,500	Closed	-$6.61M	–	77
2020 Q2	$6.61M	Sell	62,500 -32,500	-34%	-$3.36M	1.98%	22
2020 Q1	$8.48M	Buy	+95,000	New	+$8.94M	3.74%	7

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Integral Health Asset Management's AZN Position: Q1 2026 in Review

Integral Health Asset Management increased its AstraZeneca (AZN) stake by 43% in Q1 2026, buying an estimated $14.5M and bringing the position to 250,000 shares worth $49.3M. The position accounts for 2.36% of the portfolio, ranked #14.

Integral Health Asset Management first reported a position in AZN in Q1 2020 and has held it in 11 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Integral Health Asset Management held 250,000 shares of AstraZeneca worth $49.3M as of Q1 2026.
Integral Health Asset Management bought 75,000 AstraZeneca shares in Q1 2026, an estimated $14.5M.
AstraZeneca made up 2.36% of Integral Health Asset Management's portfolio in Q1 2026, its #14 holding.
Integral Health Asset Management first reported a position in AstraZeneca in Q1 2020 and has held it in 11 quarters since.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.